Experts tuning into the highly anticipated advisory committee meeting on coronavirus vaccine development and approval issues may be disappointed to learn that the US Food and Drug Administration intends to spend a lot of time level-setting.
The 22 October Vaccines and Related Biological Products Advisory Committee meeting agenda includes several presentations offering background on coronavirus disease and the federal response to the pandemic
No product-specific issues are expected to be discussed during the meeting. (See box with links to the online meeting stream